Environmental hazard assessment of Venezuelan equine encephalitis virus vaccine candidate strain V3526

Vaccine

Volumn 22, Issue 20, 2004, Pages 2667-2673

  Rao, Venkat ^a   Hinz, Matthew E ^b   Roberts, Brian A ^b   Fine, Donald ^b  

^a DynPort Vaccine Company LLC   (United States)

^b DynPort Vaccine Company LLC   (United States)

Author keywords

Biodefense; Biological countermeasures; Biosafety; Ecological risk assessment; Hazard assessment; Public health; Recombinant vaccines; Risk assessment; Select agent rule; TC 83; Venezuelan equine encephalitis

Indexed keywords

RECOMBINANT VACCINE; UNCLASSIFIED DRUG; V 3526; VENEZUELAN EQUINE ENCEPHALITIS VACCINE; VIRUS VACCINE;

AGRICULTURE; ARTICLE; BIOSAFETY; DRUG SAFETY; ENVIRONMENTAL HEALTH; HAZARD ASSESSMENT; INFECTION CONTROL; INFECTION PREVENTION; PATHOGENICITY; PRIORITY JOURNAL;

ANIMALS; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; PUBLIC HEALTH; RISK ASSESSMENT; UNITED STATES; UNITED STATES OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 2942567752     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.09.041     Document Type: Article

References (25)

1. Arya S.C. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am. J. Trop. Med. Hyg. 65:2001;v-vi
2. Ludwig G.V., Turell M.J., Vogel P., Kondig J.P., Kell W.K., Smith J.F., et al. Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice. Am. J. Trop. Med. Hyg. 64:2001;49-55
3. Steele K.E., Davis K.J., Stephan K., Kell W., Vogel P., Hart M.K. Comparative neurovirulence and tissue tropism of wild type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H/HeN and BALB/c mice. Vet. Pathol. 35:1998;386-397
4. Rotz L.D., Khan A.S., Lillibridge S.R., Ostroff S.M., Hughes J.M. Public health assessment of potential biological terrorism agents. Centers for Diseases Control Prevention (CDC). Emerg. Infect. Dis. 8:2002;225-230
5. Bronze M.S., Huycke M.M., Machado L.J., Voskuhl G.W., Greenfield R.A. Viral agents as biological weapons and agents of bioterrorism. Am. J. Med. Sci. 323:2002;316-325
6. Valero N., Henriquez R., Hernandez C., Pomeda O., Romero M., Urdaneta F., et al. Viral agents in patients with infectious processes of the central nervous system. Invest. Clin. 42:2001;255-267
7. Occupational Safety and Health Administration (OSHA). 29 CFR 1910.132 (Subpart I). Washington, DC: US Department of Labor; 1994.
8. US Environmental Protection Agency. Supplementary guidance for conducting health risk assessment of chemical mixtures. Washington, DC, 2000.
9. Codex Alimentarius Commission (Codex). Principles and guidelines for the conduct of microbiological risk assessment, CAC/GL-30. Geneva: World Health Organization; 1999.
10. World Health Organization (WHO). Report of the joint FAO/WHO expert consultation on risk assessment of microbiological hazards in foods. Ad Hoc expert consultations on risk assessment of microbiological hazards in foods. Rome, Italy, 2000.
11. International Life Sciences Institute (ILSI). Revised framework for microbial risk assessment. Washington, DC: ILSI Press; 2000.
12. Davis N.L., Brown K.W., Greenwald G.F., Zajac A.J., Zacny V.L., Smith J.F., et al. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1. Virology. 212:1995;102-110
13. Hart M.K., Caswell-Stephan K., Bakken R., Tammariello R., Pratt W., Davis N., et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine. 18:2000;3067-3075
14. Turell M.J., Ludwig G.V., Kondig J., Smith J.F. Limited potential for mosquito transmission of genetically engineered, live-attenuated Venezuelan equine encephalitis virus vaccine candidates. Am. J. Trop. Med. Hyg. 60:1999;1041-1044
15. Biological Weapons Convention (BWC). Ad Hoc group of the states parties to the convention on the prohibition of the development, production, and stockpiling of bacteriological (biological) and toxin weapons and on their destruction. BWC/AD HOC Group/WP.356. Fourteenth Session. Geneva, 1999.
16. Turell M.J., Ludwig G.V., Beaman J.R. Transmission of Venezuelan equine encephalomyelitis virus by Aedes sollicitans and Aedes taeniorhynchus (diptera: culicidae). J. Med. Entomol. 29:1992;62-65
17. Pratt WD, Davis NL, Johnson RE, Smith JF. Genetically engineered, live attenuated vaccines for venezuelan equine encephalitis: testing in animal models. Vaccine 2003;21:3854-3862.
18. Bowen RA, Powers AK. Safety and efficacy evaluation of new VEE vaccine candidate, V3526, in horses, 2003, unpublished data.
19. Centers for Disease Control and Prevention (CDC). Biological and chemical terrorism: strategic plan for preparedness and response, recommendations of the CDC strategic planning workgroup. MMWR Morb Mortal Wkly Rep 2000;49:1-14.
20. US Environmental Protection Agency. Guidelines for carcinogen risk assessment. 51 Federal Register 33992. Washington, DC; 24 September 1986.
21. US Environmental Protection Agency. Risk assessment guidance for superfund. Human Health Evaluation Manual (Part A); 1989. p. 1.
22. International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans, Suppl 4. Lyon, France, 1992.
23. Johnston RE, Peters CJ, Alphaviruses. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology. Philadelphia: Lippincott-Raven; 1996. p. 843-98.
24. Smith JF, Davis K, Pratt WD, Parker MD, McClain DJ, Ludwig GV, et al. Textbook of military medicine: medical aspects of chemical and biological warfare. Viral encephalitides; 1997. p. 561-89.
25. Walton TE, Grayson MA. Venezuelan equine encephalomyelitis. In: Monath TP, editor. The arboviruses: epidemiology and ecology. Boca Raton, FL: CRC Press; 1989. p. 203-31.